GLP-1 Medications and Cancer Risk: What the Research Shows
Recent studies of over 1.6 million patients suggest GLP-1 medications may reduce risk of 10 obesity-associated cancers — but a thyroid signal still demands attention. Here's the evidence.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on April 27, 2026
Our medical review process ensures clinical accuracy and patient safety.
Obesity is one of the most powerful modifiable risk factors for cancer — second only to tobacco. The International Agency for Research on Cancer has linked excess body weight to at least 13 distinct malignancies, from colorectal and endometrial cancer to esophageal adenocarcinoma and multiple myeloma. So when GLP-1 receptor agonists like semaglutide and tirzepatide began producing 15–22% weight loss in clinical trials, oncologists asked the obvious question: could these drugs also lower cancer risk?
A 2024 cohort study of more than 1.6 million patients with type 2 diabetes found that GLP-1 receptor agonist users had a significantly reduced risk of 10 of 13 obesity-associated cancers compared with insulin users.
Evidence: "GLP-1 receptor agonists, compared with insulins, were associated with a significant risk reduction in 10 of 13 obesity-associated cancers, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer as well as meningioma and multiple myeloma" — Wang L, et al. JAMA Network Open. 2024. DOI: 10.1001/jamanetworkopen.2024.21305
The picture is nuanced, however. Newer randomized data confirm no excess overall cancer risk and probable benefit in obesity-driven malignancies — yet a small thyroid cancer signal continues to surface in long-term analyses, and the FDA still maintains a boxed warning rooted in rodent studies. Understanding which findings are robust and which remain hypothesis-generating is essential for anyone weighing GLP-1 therapy.
What "Obesity-Associated Cancer" Actually Means
Roughly 1 in 25 cancers in adults is attributable to excess body fat, with that figure rising sharply in postmenopausal women and patients with type 2 diabetes. The mechanisms link adiposity to malignant transformation through three overlapping pathways:
- Hyperinsulinemia and IGF-1 signaling — chronically elevated insulin promotes cell proliferation and inhibits apoptosis in tissues like the colon, endometrium, and liver
- Chronic low-grade inflammation — visceral adipose tissue secretes pro-tumorigenic cytokines (TNF-α, IL-6, leptin) that create a permissive microenvironment for cancer initiation
- Sex hormone dysregulation — adipose-derived aromatase converts androgens to estrogens, raising risk of hormone-sensitive cancers including endometrial and postmenopausal breast cancer
Because GLP-1 receptor agonists improve all three axes — insulin sensitivity, inflammation, and adiposity itself — there is biological plausibility for a chemopreventive effect, particularly in the cancers most tightly tied to metabolic dysfunction. For broader context on how these drugs reshape metabolism, see our breakdown of GLP-1 medications and inflammation.
The Population-Level Evidence: Reduced Cancer Risk
Wang et al., 2024 — The Landmark Cohort
The most influential dataset to date comes from a retrospective cohort of 1,651,452 adults with type 2 diabetes and no prior diagnosis of obesity-associated cancer, drawn from a multi-institutional U.S. electronic health record network. Patients were followed for up to 15 years after initiation of GLP-1 receptor agonists, insulin, or metformin.
| Cancer type | GLP-1 vs insulin (HR) | Statistical significance |
|---|---|---|
| Gallbladder | 0.35 | Significant |
| Meningioma | 0.37 | Significant |
| Pancreatic | 0.41 | Significant |
| Hepatocellular | 0.47 | Significant |
| Ovarian | 0.52 | Significant |
| Colorectal | 0.54 | Significant |
| Multiple myeloma | 0.59 | Significant |
| Esophageal | 0.60 | Significant |
| Endometrial | 0.74 | Significant |
| Kidney | 0.76 | Significant |
| Postmenopausal breast | 0.96 | Not significant |
| Stomach | 0.94 | Not significant |
| Thyroid | 0.83 | Not significant |
Critically, GLP-1 users were not found to have lower risk than metformin users for most cancers — a reminder that metformin itself has well-documented antineoplastic properties, and the bar for "better than metformin" is exceptionally high.
Mali et al., 2025 — GLP-1 vs Bariatric Surgery
A larger question was whether GLP-1 drugs match the cancer-protective effect of bariatric surgery, long considered the gold standard for metabolic remission.
Evidence: "In adults with obesity, first-line GLP-1RA therapy was associated with a similar risk of obesity-related cancer compared with bariatric metabolic surgery, despite achieving less weight loss" — Mali G, et al. eClinicalMedicine. 2025. DOI: 10.1016/j.eclinm.2025.103230
This is striking. Bariatric surgery typically produces 25–35% total body weight loss versus 15–22% for current GLP-1 drugs, and yet the cancer outcomes were comparable. The implication: weight loss alone may not fully explain the chemopreventive effect — direct receptor-mediated actions on tumor biology likely contribute.
What Randomized Trials Show
Observational data are vulnerable to confounding by indication: patients prescribed GLP-1 drugs differ from those given insulin in ways (BMI, comorbidity burden, healthcare engagement) that also affect cancer risk. Randomized trials are the corrective lens.
The most comprehensive synthesis to date pooled 50 placebo-controlled RCTs of GLP-1 receptor agonists with at least 6 months of follow-up.
Evidence: "GLP-1 receptor agonist treatment was not associated with a significant difference in risk for overall cancer compared with placebo. Uterine cancer was significantly reduced in GLP-1RA arms in trials performed in subjects with obesity" — Silverii GA, et al. Diabetes, Obesity and Metabolism. 2025. DOI: 10.1111/dom.16489
A separate 2026 systematic review in Annals of Internal Medicine examined both pure GLP-1 receptor agonists and dual incretin agonists (such as tirzepatide).
Evidence: "Use of GLP-1 receptor agonists and dual agonists was not associated with an increased risk for overall or site-specific cancers, including pancreatic and gastrointestinal malignancies, in randomized trials with up to 5 years of follow-up" — Annals of Internal Medicine. 2026; 179(2). DOI: 10.7326/ANNALS-25-02237
The convergent message from RCTs: no signal of harm for overall, gastrointestinal, or pancreatic cancers. The signal of benefit in obesity-related malignancies — particularly uterine cancer — appears specifically in obesity trials rather than diabetes trials, suggesting the chemopreventive effect tracks with degree of weight loss and metabolic improvement.
The Thyroid Cancer Question
No discussion of GLP-1 oncology is complete without addressing the boxed warning on every package of semaglutide, liraglutide, and tirzepatide.
What the rodent data actually showed
In two-year carcinogenicity studies, rats exposed to liraglutide and semaglutide developed thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) at higher rates than controls. The mechanism appears to be sustained activation of GLP-1 receptors on rodent thyroid C-cells, which proliferate in response.
The translatability is unclear. Human thyroid C-cells express GLP-1 receptors at far lower density than rat C-cells, and most clinical analyses to date have not detected an MTC signal in humans. Nonetheless, the FDA requires the boxed warning and contraindicates these drugs in patients with personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2).
What human data show
Evidence: "Across 10 studies analyzing thyroid cancer outcomes with semaglutide, incidence was notably low, with isolated cases of papillary and medullary thyroid cancer each constituting less than 1% within the respective study groups, suggesting no significant risk for thyroid cancer associated with semaglutide use" — Bea S, et al. Cancers (Basel). 2024. PMC11050669
The Silverii 2025 meta-analysis did detect a numerically increased thyroid cancer signal in longer-duration trials, though it remained nonsignificant in absolute terms. Whether this reflects a true low-magnitude risk, surveillance bias (more imaging in patients on GLP-1 drugs), or statistical noise will require follow-up beyond the 2–4 year horizon of most existing trials.
For practical purposes:
- Patients with a history of MTC or MEN2 should not use GLP-1 receptor agonists
- Routine thyroid ultrasound or calcitonin screening is not recommended for asymptomatic patients on these drugs
- New neck masses, persistent hoarseness, or dysphagia warrant evaluation, as they would in any patient
For broader context on thyroid effects, see our deep dive on GLP-1 medications and thyroid health.
Pancreatic Cancer: A Persistent Question, Largely Resolved
Early case reports of pancreatitis in GLP-1 users led to concerns about pancreatic cancer, since chronic pancreatitis is itself a risk factor for ductal adenocarcinoma. Two decades of postmarketing data and randomized trials have substantially clarified this picture.
Evidence: "Meta-analysis of randomized controlled trials demonstrated a significantly increased risk of pancreatitis with GLP-1 receptor agonists, but no significant association with pancreatic cancer was observed across the included trials" — Pancreatitis and pancreatic cancer with GLP-1 receptor agonists: a systematic review and meta-analysis. 2025. PubMed: 40988099
The clinical picture: acute pancreatitis is a real, low-frequency adverse event (roughly 0.1–0.2% per year, perhaps 1.5–2× background rate). Pancreatic cancer is not increased. In Wang's cohort study, GLP-1 users actually had 59% lower pancreatic cancer risk than insulin users.
Where This Leaves Patients and Clinicians
Cancer risk should not be the primary driver of any decision to start or stop a GLP-1 medication. The trial evidence supporting cardiovascular and metabolic benefit is far more mature than the cancer evidence, and the magnitude of those proven benefits dwarfs whatever chemopreventive effect ultimately emerges.
That said, several principles are now well-supported:
- No overall cancer risk increase. Across 50+ RCTs and over 1.6 million person-years of observational data, GLP-1 receptor agonists do not raise total cancer risk.
- Probable reduction in obesity-driven malignancies. The strongest signal is in uterine, colorectal, hepatocellular, gallbladder, and pancreatic cancer — particularly in patients with high baseline metabolic dysfunction.
- Postmenopausal breast cancer is a non-finding. Despite the obesity-breast cancer link, GLP-1 drugs have not shown a protective effect here in the largest analyses.
- Thyroid C-cell concern remains theoretical in humans but warrants screening for personal/family MTC history before prescribing.
- Pancreatic cancer concern is essentially resolved. Pancreatitis risk exists; pancreatic cancer risk does not appear increased.
Conclusion
The clinical evidence on GLP-1 medications and cancer has matured rapidly. What began as a worry — driven by rodent thyroid tumors and pancreatitis case reports — has shifted to a cautious optimism that these drugs may prevent some of the most common obesity-driven cancers. The headline finding from Wang's 1.6-million-patient cohort, replicated in part by RCT meta-analyses, is that GLP-1 receptor agonists associate with substantially lower rates of 10 obesity-related malignancies.
Long-term oncology trials with cancer as the primary endpoint are now underway, and the next five years should clarify which of these signals reflect true chemoprevention versus residual confounding. For patients already on a GLP-1 drug for diabetes or obesity, the current evidence is reassuring — and for those with strong obesity-related cancer family histories, it adds one more weight to the side of treatment.
References
Wang L, Wang W, Kaelber DC, et al. GLP-1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Network Open. 2024;7(7):e2421305. DOI: 10.1001/jamanetworkopen.2024.21305 | PubMed
Silverii GA, Dicembrini I, Monami M, et al. GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2025;27(8):4012-4023. DOI: 10.1111/dom.16489 | PubMed
Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Annals of Internal Medicine. 2026;179(2). DOI: 10.7326/ANNALS-25-02237
Mali G, Ahmed A, Stenberg E, et al. Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer. eClinicalMedicine. 2025;83:103230. DOI: 10.1016/j.eclinm.2025.103230
Bea S, Son H, Bae JH, et al. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide Therapy: A Systematic Literature Review. Cancers (Basel). 2024;16(8):1419. PMC11050669
Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. 2025. PubMed: 40988099
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncology. 2025. PubMed: 40839273
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. Journal of Clinical Investigation. 2025. PMC12578377
Last updated: 2026-04-27 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.